Medication Safety
Restricted Distribution of Pharmaceuticals Policy 0119 11/01/2001 Introduced 02/01/2006 Revised 12/01/2010 Revised 04/07/2015 Revised 04/29/2020 Revised | AMCP generally opposes any restrictions on the distribution of pharmaceutical products either by the pharmaceutical industry or as a condition for FDA-approval. AMCP acknowledges that circumstances may occur with the use of specific medications that require special distribution, monitoring and management processes. As long as,
1. The requirements do not interfere with the continuity of care for the patient or limit patient access; 2. The requirements preserve the pharmacist-patient relationship and patient choice of pharmacy; 3. The requirements are based on evidence-based medicine, fully disclosed and evaluated by physicians, pharmacists, and others; 4. There is scientific consensus that the requirements are necessary and represent the least restrictive means to achieve safe and effective patient care; 5. The cost of the product and any associated product or services are identified for purposes of reimbursement, mechanisms are provided to compensate providers for special services, and duplicative costs are avoided; 6. All requirements are stated in functional, objective terms so that any provider who meets the criteria may participate in the care of patients; 7. The requirements do not interfere with the professional practice of pharmacists, physicians, or other appropriately qualified healthcare professionals; (The enumerated principles are drawn from ASHP Principles for Restricted Distribution Systems) |
Featured News & Resources
See Full CalendarHBCU Travel Awards for AMCP25
Mid-South AMCP Day of Education 2025
Southwest AMCP Annual Day of Education 2025
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.